Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs WEC Energy Group Inc. Common Stock (WEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs WEC Energy Group Inc. Common Stock — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.93 (market cap $6.43B), while WEC Energy Group Inc. Common Stock trades at $107.87 (market cap $34.78B). The key difference: WEC Energy Group Inc. Common Stock is far larger — about 5.4× Iovance Biotherapeutics Inc. Common Stock's market cap, and WEC Energy Group Inc. Common Stock pays a 3.57% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 1 Days and WEC Energy Group Inc. Common Stock for 0 Days on average.
| IOVA | WEC | |
|---|---|---|
Market Cap | $6.43B | $34.78B |
Volume | 10,599,472 | 2,317,952 |
Sector | Health | Utilities |
52-Week High | $14.82 | $118.85 |
52-Week Low | $1.81 | $100.78 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $6.37B | $57.74B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
WEC Energy Group trades at $105.87, up 0.92% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $0.91 vs. $0.804 expected) and improving profitability (net margin 16.7%). Recent news highlights growing data center demand as a key growth driver, with the company engaging in large-scale customer discussions for 400-500 megawatt projects.
WEC presents a compelling utility investment with stable cash flows and dividend potential, though faces interest rate sensitivity. Analyst consensus targets $118.33 (12% upside) with majority Hold ratings. Key risks include regulatory pressures and capital expenditure requirements for infrastructure expansion through 2030.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About WEC Energy Group Inc. Common Stock
WEC Energy Group is a Midwest electric and natural gas utility holding company whose subsidiaries, including We Energies and Wisconsin Public Service, deliver electricity and natural gas to customers in Wisconsin, Illinois, Michigan, and Minnesota.
Read more on WEC →
